Emerging Therapies Broaden Options for Chronic Spontaneous Urticaria
At the American Academy of Dermatology meeting, experts highlighted new and emerging treatments for chronic spontaneous urticaria, including IL-4 receptor blockade, BTK inhibition, and c-KIT/mast cell strategies. Remibrutinib, dupilumab, and barzolvolimab were among the therapies discussed as promising advances. A dermatologist said the treatment future for CSU and chronic inducible urticaria appears bright.
At the AAD meeting, a session examined chronic spontaneous urticaria and chronic inducible urticaria. Brian Kim, a dermatology professor and research vice chair at Mount Sinai, discussed remibrutinib, a newly approved BTK inhibitor, and noted phase III data across dermatographism, cold urticaria, and cholinergic urticaria.
Dupilumab was also highlighted for chronic spontaneous urticaria. Barzolvolimab, a c-KIT inhibitor, may both suppress and deplete mast cells. Kim disclosed co-founding Alys Pharma, which is developing a bispecific c-KIT inhibitor intended to act on mast cells.
People living with chronic hives and related inducible forms could gain more treatment choices if these approaches reach practice. Better control may reduce itching, sleep disruption, and unpredictability, potentially improving daily life for patients and caregivers. Clinicians may need to weigh efficacy, safety, monitoring, and access. Long-term data and cost could determine how broadly these options help.